The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer

被引：28

作者：

Engelman, Jeffrey A.

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA

[2] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA

[3] Beth Israel Deaconess Med Ctr, Dept Signal Transduct, Boston, MA 02215 USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 15期

关键词：

D O I：

10.1158/1078-0432.CCR-07-0653

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The phosphoinositide 3-kinase signaling network is widely implicated in the pathogenesis of human cancer. This pathway is commandeered by cancer cells to promote unrestrained cellular growth and survival. In this brief review, we speculate about the uses of inhibitors of phosphoinositide 3-kinase signaling as treatments for human cancers,with an emphasis on non-small cell lung cancer.

引用

收藏

页码：4637S / 4640S

页数：4

相关论文

共 29 条

[1] Oncogenic PI3K deregulates transcription and translation [J].

Bader, AG ;

Kang, SY ;

Zhao, L ;

Vogt, PK .

NATURE REVIEWS CANCER, 2005, 5 (12) :921-929

[2] Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].

Bianco, R ;

Shin, I ;

Ritter, CA ;

Yakes, FM ;

Basso, A ;

Rosen, N ;

Tsurutani, J ;

Dennis, PA ;

Mills, GB ;

Arteaga, CL .

ONCOGENE, 2003, 22 (18) :2812-2822

[3]

Bjorkqvist AM, 1998, GENE CHROMOSOME CANC, V22, P79

[4]

Brognard J, 2001, CANCER RES, V61, P3986

[5] hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase [J].

Byfield, MP ;

Murray, JT ;

Backer, JM .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (38) :33076-33082

[6] The phosphoinositide 3-kinase pathway [J].

Cantley, LC .

SCIENCE, 2002, 296 (5573) :1655-1657

[7] Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer [J].

Carretero, J. ;

Medina, P. P. ;

Blanco, R. ;

Smit, L. ;

Tang, M. ;

Roncador, G. ;

Maestre, L. ;

Conde, E. ;

Lopez-Rios, F. ;

Clevers, H. C. ;

Sanchez-Cespedes, M. .

ONCOGENE, 2007, 26 (11) :1616-1625

[8] Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage [J].

David, O ;

Jett, J ;

LeBeau, H ;

Dy, G ;

Hughes, J ;

Friedman, M ;

Brody, AR .

CLINICAL CANCER RESEARCH, 2004, 10 (20) :6865-6871

[9] Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer [J].

Engelman, Jeffrey A. ;

Mukohara, Toru ;

Zejnullahu, Kreshnik ;

Lifshits, Eugene ;

Borras, Ana M. ;

Gale, Christopher-Michael ;

Naumov, George N. ;

Yeap, Beow Y. ;

Jarrell, Emily ;

Sun, Jason ;

Tracy, Sean ;

Zhao, Xiaojun ;

Heymach, John V. ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (10) :2695-2706

[10] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism [J].

Engelman, Jeffrey A. ;

Luo, Ji ;

Cantley, Lewis C. .

NATURE REVIEWS GENETICS, 2006, 7 (08) :606-619